Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to observe and evaluate the efficacy and safety of SHR-1210 combined with preoperative chemotherapy or Apatinib for locally advanced esophageal squamous cell carcinoma


Clinical Trial Description

In China, the incidence of esophageal cancer has declined in recent years, but the mortality rate has been ranked fourth. Morbidity and mortality were ranked sixth and fourth in all malignancies, respectively. Therefore, esophageal cancer has always been a major malignant tumor that threatens the health of our residents. Investigator designed a single-arm, open-label, phase II trial of SHR-1210 combined with preoperative chemotherapy or Apatinib for locally advanced esophageal squamous cell carcinoma. The purpose of this study is to observe and evaluate the efficacy and safety of SHR-1210 combined with preoperative chemotherapy or Apatinib for locally advanced esophageal squamous cell carcinoma. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03917966
Study type Interventional
Source The First Affiliated Hospital of Zhengzhou University
Contact Feng Wang
Phone 13938244776
Email fengw010@163.com
Status Recruiting
Phase Phase 2
Start date April 7, 2020
Completion date October 7, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05743504 - Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients Phase 1/Phase 2
Recruiting NCT05520619 - Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002) Phase 2
Recruiting NCT04602013 - Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma Phase 2
Not yet recruiting NCT05522894 - AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC Phase 2
Active, not recruiting NCT03914443 - A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma Phase 1
Not yet recruiting NCT06426797 - Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma Phase 2
Active, not recruiting NCT06342167 - Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT06187597 - Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) Phase 2
Recruiting NCT05130684 - Neo-NTP-CRT for Locally Advanced ESCC Phase 2
Not yet recruiting NCT04888403 - Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma Phase 2
Not yet recruiting NCT06356688 - A Clinical Study on the Efficacy and Safety of Paclitaxel Polymer Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma Phase 2